Vivo Capital LLC Purchases Shares of 722,020 Sensei Biotherapeutics, Inc. $FTH

Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 722,020 shares of the company’s stock, valued at approximately $22,758,000. Sensei Biotherapeutics comprises about 1.9% of Vivo Capital LLC’s investment portfolio, making the stock its 19th biggest holding. Vivo Capital LLC owned approximately 53.88% of Sensei Biotherapeutics as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares during the period. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Trading Down 0.4%

Shares of NASDAQ:FTH opened at $28.82 on Friday. The company has a market cap of $38.62 million, a price-to-earnings ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 1-year low of $7.10 and a 1-year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Sensei Biotherapeutics, Inc. will post -16.61 EPS for the current fiscal year.

Insider Activity at Sensei Biotherapeutics

In related news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Brian C. Stephenson purchased 5,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was acquired at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the purchase, the chief financial officer directly owned 46,688 shares in the company, valued at $1,097,168. This trade represents a 11.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on FTH shares. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research note on Tuesday. They issued an “outperform” rating and a $60.00 price objective for the company. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 target price on the stock. Leerink Partners initiated coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.75.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.